FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011493722> ?p ?o ?g. }

• W2011493722 endingPage "99" @default.
• W2011493722 startingPage "91" @default.
• W2011493722 abstract "The aim of this paper is to propose a pharmaceutical risk assessment strategy that goes beyond the usual characterisation of a clinical candidate molecule according to the biopharmaceutical classification system (BCS). This strategy was evaluated for a new CNS drug with poor solubility and good permeability. In a first step, GastroPlus™ was used to simulate the absorption process based on preformulation data. These input data involved a physicochemical drug characterisation including drug solubility measurements in simulated physiological media, as well as permeability determination. Further computer simulations were conducted to determine the sensitivity to changes of selected input values. Thus, oral bioavailability prediction was studied as a function of the particle size and drug solubility. The second part of the presented strategy for preclinical formulation development was to test specially designed formulations in a 23 screening factorial plan using the dog as the animal model. The factors were the dosage form, food effect and dose strength. One of the two experimental formulations was a capsule filled with the micronised drug, whereas the other formulation was a surfactant solution of the drug. Accordingly, a “worst case” formulation was compared with a “best case” drug solution over the clinically relevant dose range in fasted and fed dogs. The results of the computer simulation indicated that a fraction of the dose is dissolved in the stomach and precipitates partially in the small intestine. The simulation predicted almost full drug absorption during the GI transit time. Interestingly, the simulation implies that stomach drug solubility had little impact on overall fraction absorbed. The results also showed that changes of particle size and reference solubility within two orders of magnitude hardly affected the oral bioavailability. This in silico deduction was subsequently compared with the results of the dog studies. Indeed a surfactant drug solution showed no clear biopharmaceutical superiority over a solid capsule formulation on the average of both dose strengths in fasted and fed dogs. Despite the substantial variability of the in vivo data, the factorial screening design indicated marginal significant interaction between the dose level and feeding status. This can be viewed as a flag for the planning of further studies, since a potential effect of one factor may depend on the level of the other. In summary, the GastroPlus™ simulation together with the statistically designed dog study provided a thorough biopharmaceutical assessment of the new CNS drug. Based on these findings, it was decided to develop a standard granulate in capsules for phase I studies. More sophisticated formulation options were abandoned and so the clinical formulation development was conducted in a cost-efficient way." @default.
• W2011493722 created "2016-06-24" @default.
• W2011493722 creator A5002364347 @default.
• W2011493722 creator A5006080071 @default.
• W2011493722 creator A5055401474 @default.
• W2011493722 creator A5085106792 @default.
• W2011493722 date "2006-01-01" @default.
• W2011493722 modified "2023-10-11" @default.
• W2011493722 title "A strategy for preclinical formulation development using GastroPlus™ as pharmacokinetic simulation tool and a statistical screening design applied to a dog study" @default.
• W2011493722 cites W1498305210 @default.
• W2011493722 cites W1499768710 @default.
• W2011493722 cites W1501546570 @default.
• W2011493722 cites W1522767714 @default.
• W2011493722 cites W1972523776 @default.
• W2011493722 cites W1974875661 @default.
• W2011493722 cites W1979063088 @default.
• W2011493722 cites W1980152357 @default.
• W2011493722 cites W2019392143 @default.
• W2011493722 cites W2020446438 @default.
• W2011493722 cites W2032865438 @default.
• W2011493722 cites W2049391578 @default.
• W2011493722 cites W2050880349 @default.
• W2011493722 cites W2067794000 @default.
• W2011493722 cites W2081047989 @default.
• W2011493722 cites W2107566417 @default.
• W2011493722 cites W2113953460 @default.
• W2011493722 cites W2149429360 @default.
• W2011493722 cites W68169567 @default.
• W2011493722 doi "https://doi.org/10.1016/j.ejps.2005.08.011" @default.
• W2011493722 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16219449" @default.
• W2011493722 hasPublicationYear "2006" @default.
• W2011493722 type Work @default.
• W2011493722 sameAs 2011493722 @default.
• W2011493722 citedByCount "98" @default.
• W2011493722 countsByYear W20114937222012 @default.
• W2011493722 countsByYear W20114937222013 @default.
• W2011493722 countsByYear W20114937222014 @default.
• W2011493722 countsByYear W20114937222015 @default.
• W2011493722 countsByYear W20114937222016 @default.
• W2011493722 countsByYear W20114937222017 @default.
• W2011493722 countsByYear W20114937222018 @default.
• W2011493722 countsByYear W20114937222019 @default.
• W2011493722 countsByYear W20114937222020 @default.
• W2011493722 countsByYear W20114937222021 @default.
• W2011493722 countsByYear W20114937222022 @default.
• W2011493722 crossrefType "journal-article" @default.
• W2011493722 hasAuthorship W2011493722A5002364347 @default.
• W2011493722 hasAuthorship W2011493722A5006080071 @default.
• W2011493722 hasAuthorship W2011493722A5055401474 @default.
• W2011493722 hasAuthorship W2011493722A5085106792 @default.
• W2011493722 hasConcept C105795698 @default.
• W2011493722 hasConcept C106186310 @default.
• W2011493722 hasConcept C112705442 @default.
• W2011493722 hasConcept C125287762 @default.
• W2011493722 hasConcept C150903083 @default.
• W2011493722 hasConcept C155574463 @default.
• W2011493722 hasConcept C159985019 @default.
• W2011493722 hasConcept C169222746 @default.
• W2011493722 hasConcept C178790620 @default.
• W2011493722 hasConcept C178855305 @default.
• W2011493722 hasConcept C181389837 @default.
• W2011493722 hasConcept C185592680 @default.
• W2011493722 hasConcept C192562407 @default.
• W2011493722 hasConcept C2780035454 @default.
• W2011493722 hasConcept C2781047461 @default.
• W2011493722 hasConcept C33923547 @default.
• W2011493722 hasConcept C43617362 @default.
• W2011493722 hasConcept C71924100 @default.
• W2011493722 hasConcept C77281830 @default.
• W2011493722 hasConcept C86803240 @default.
• W2011493722 hasConcept C98274493 @default.
• W2011493722 hasConceptScore W2011493722C105795698 @default.
• W2011493722 hasConceptScore W2011493722C106186310 @default.
• W2011493722 hasConceptScore W2011493722C112705442 @default.
• W2011493722 hasConceptScore W2011493722C125287762 @default.
• W2011493722 hasConceptScore W2011493722C150903083 @default.
• W2011493722 hasConceptScore W2011493722C155574463 @default.
• W2011493722 hasConceptScore W2011493722C159985019 @default.
• W2011493722 hasConceptScore W2011493722C169222746 @default.
• W2011493722 hasConceptScore W2011493722C178790620 @default.
• W2011493722 hasConceptScore W2011493722C178855305 @default.
• W2011493722 hasConceptScore W2011493722C181389837 @default.
• W2011493722 hasConceptScore W2011493722C185592680 @default.
• W2011493722 hasConceptScore W2011493722C192562407 @default.
• W2011493722 hasConceptScore W2011493722C2780035454 @default.
• W2011493722 hasConceptScore W2011493722C2781047461 @default.
• W2011493722 hasConceptScore W2011493722C33923547 @default.
• W2011493722 hasConceptScore W2011493722C43617362 @default.
• W2011493722 hasConceptScore W2011493722C71924100 @default.
• W2011493722 hasConceptScore W2011493722C77281830 @default.
• W2011493722 hasConceptScore W2011493722C86803240 @default.
• W2011493722 hasConceptScore W2011493722C98274493 @default.
• W2011493722 hasIssue "1" @default.
• W2011493722 hasLocation W20114937221 @default.
• W2011493722 hasLocation W20114937222 @default.
• W2011493722 hasOpenAccess W2011493722 @default.
• W2011493722 hasPrimaryLocation W20114937221 @default.
• W2011493722 hasRelatedWork W1483644003 @default.

• next